These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32841341)

  • 1. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.
    Pemmaraju N; Konopleva M
    Blood Adv; 2020 Aug; 4(16):4020-4027. PubMed ID: 32841341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jen EY; Gao X; Li L; Zhuang L; Simpson NE; Aryal B; Wang R; Przepiorka D; Shen YL; Leong R; Liu C; Sheth CM; Bowen S; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2020 Feb; 26(3):532-536. PubMed ID: 31548341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
    Lee SS; McCue D; Pemmaraju N
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
    Tandon A; Zhang Y; Sokol L
    Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; McCue D; Lane AA; Pemmaraju N
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
    [No Abstract]   [Full Text] [Related]  

  • 6. Tagraxofusp and anti-CD123 in blastic plasmacytoid dendritic cell neoplasm: a new hope.
    Cangini D; Silimbani P; Cafaro A; Giannini MB; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):467-477. PubMed ID: 32955827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting.
    Dhakal P; Sy M; Sutamtewagul G; Mou E; Yu N; Pemmaraju N
    J Immunother Precis Oncol; 2024 Aug; 7(3):205-209. PubMed ID: 39219995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Wilson NR; Pemmaraju N
    Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Luskin MR; Lane AA
    Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Alfayez M; Konopleva M; Pemmaraju N
    Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
    Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
    Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature.
    Jen WY; Konopleva M; Pemmaraju N
    Cancer; 2024 Jul; 130(13):2260-2271. PubMed ID: 38620053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Deconinck E; Mehta P; Walker I; Herling M; Garnache-Ottou F; Gabarin N; Campbell CJV; Duell J; Moshe Y; Mughal T; Mohty M; Angelucci E
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e130-e137. PubMed ID: 38267355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tagraxofusp: First Global Approval.
    Syed YY
    Drugs; 2019 Apr; 79(5):579-583. PubMed ID: 30859413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tagraxofusp in myeloid malignancies.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
    Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Zhang Y; Sokol L
    Cancer Manag Res; 2022; 14():2107-2117. PubMed ID: 35789956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.